Beyond Medicine: Nutraceutical Approaches for Comprehensive Management of Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome (PCOS) is a common endocrine and metabolic disorder characterized by ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. Insulin resistance, adipose tissue dysfunction, oxidative stress, chronic low-grade inflammation, mitochondrial impairment, and altered insulin-signaling pathways are all part of the multifactorial etiology of PCOS, which leads to hyperandrogenism and metabolic disorders. This review emphasizes how dietary changes, vitamins and minerals, nutraceuticals, antioxidants, herbal extracts, and traditional pharmaceutical treatments might help manage PCOS. Investigation indicates that dietary and lifestyle changes can considerably lower obesity, increase insulin sensitivity, and restore ovulatory function. Nutraceuticals have shown positive impacts on metabolic and reproductive outcomes, making them interesting adjuncts in the management of PCOS. Herbal remedies like curcumin, berberine, and cinnamon have demonstrated promising effect in enhancing metabolic health and hormonal balance. Supplementing with necessary vitamins and minerals may also promote healing and general health. In order to improve health outcomes and the quality of life for women with PCOS, this review highlights the significance of including dietary recommendations and nutraceutical therapies into PCOS therapy.

Women Health, Diagnosis, PCOS, Nutraceutical, Antioxidant, Vitamins, Lifestyle, Herbal Extracts

1. Teede HJ, Tay CT, Laven JJ, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European journal of endocrinology. 2023 Aug;189(2):G43-64. [Google Scholar] [Crossref]

2. Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ. Polycystic ovary syndrome. The lancet Diabetes & endocrinology. 2022 Sep 1;10(9):668-80. [Google Scholar] [Crossref]

3. Deans R. Polycystic ovary syndrome in adolescence. Medical Sciences. 2019 Oct 2;7(10):101. [Google Scholar] [Crossref]

4. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new?. Advances in clinical and experimental medicine. 2017;26(2). [Google Scholar] [Crossref]

5. Buerger C, Richter B, Woth K, Salgo R, Malisiewicz B, Diehl S, Hardt K, Boehncke S, Boehncke WH. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. Journal of Investigative Dermatology. 2012 Sep 1;132(9):2206-14. [Google Scholar] [Crossref]

6. Çelik ZM, Kurnaz D, Özcan A, Keskin E, Sayın Ünlügedik E, Aktaç Ş. The effect of nutraceutical interventions on reproductive health outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2025 Nov 24. [Google Scholar] [Crossref]

7. Muhammed Saeed AA, Noreen S, Awlqadr FH, Farooq MI, Qadeer M, Rai N, Farag HA, Saeed MN. Nutritional and herbal interventions for polycystic ovary syndrome (PCOS): a comprehensive review of dietary approaches, macronutrient impact, and herbal medicine in management. Journal of Health, Population and Nutrition. 2025 May 2;44(1):143. [Google Scholar] [Crossref]

8. Saidunnnisa G, Begum GS, Shariff A, Ayman G, Mohammad B, Housam R, Khaled N. Assessment of Risk Factors for development of Polycystic Ovarian Syndrome Clinical Skills-teaching made effective View project Assessment of Risk Factors for development of Polycystic Ovarian Syndrome View Project Assessment of Risk Factors for development. Int. J. Contemp. Med. Res. 2017;4:2454-7379. [Google Scholar] [Crossref]

9. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology & Metabolism. 1998 Sep 1;83(9):3078-82. [Google Scholar] [Crossref]

10. Yen SS. The polycystic ovary syndrome. Clinical endocrinology. 1980 Feb;12(2):177-208. [Google Scholar] [Crossref]

11. Stein IF, Leventhal ML. Amenorrhea associated with polycystic ovary syndrome. Am J Obstet Gynecol. 1935;29:181-91. [Google Scholar] [Crossref]

12. Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Archives of gynecology and obstetrics. 2006 Jul;274(4):187-97. [Google Scholar] [Crossref]

13. Scannell N, Mantzioris E, Rao V, Pandey C, Ee C, Mousa A, Moran L, Villani A. Type and Frequency in Use of Nutraceutical and Micronutrient Supplementation for the Management of Polycystic Ovary Syndrome: A Systematic Scoping Review. Biomedicines. 2023 Dec 18;11(12):3349. [Google Scholar] [Crossref]

14. Teede HJ, Tay CT, Laven JJ, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European journal of endocrinology. 2023 Aug;189(2):G43-64. [Google Scholar] [Crossref]

15. Peña AS, Codner E, Witchel S. Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review. Diagnostics (Basel). 2022 Aug 10;12(8):1931. doi: 10.3390/diagnostics12081931. PMID: 36010282; PMCID: PMC9406411. [Google Scholar] [Crossref]

16. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018 May;14(5):270-84. [Google Scholar] [Crossref]

17. Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Insulin: The master regulator of glucose metabolism. Metabolism. 2022 Apr 1;129:155142. [Google Scholar] [Crossref]

18. Titchenell PM, Lazar MA, Birnbaum MJ. Unraveling the regulation of hepatic metabolism by insulin. Trends in Endocrinology & Metabolism. 2017 Jul 1;28(7):497-505. [Google Scholar] [Crossref]

19. Qu X, Donnelly R. Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome. International journal of molecular sciences. 2020 Nov 1;21(21):8191. [Google Scholar] [Crossref]

20. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2007 Jun 1;92(6):2017-29. [Google Scholar] [Crossref]

21. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, Hu FB. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes care. 2013 May 1;36(5):1422-8. [Google Scholar] [Crossref]

22. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes care. 2010 Oct 1;33(10):2238-43. [Google Scholar] [Crossref]

23. Fiorentini D, Cappadone C, Farruggia G, Prata C. Magnesium: Biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency. Nutrients 2021, 13, 1136. Magnesium in Human Health and Disease. 2021:5. [Google Scholar] [Crossref]

24. Kogan S, Sood A, Garnick MS. Zinc and Wound Healing: A Review of Zinc Physiology and Clinical Applications. Wounds. 2017 Apr;29(4):102-106. PMID: 28448263. [Google Scholar] [Crossref]

25. Hajizadeh-Sharafabad F, Moludi J, Tutunchi H, Taheri E, Izadi A, Maleki V. Selenium and polycystic ovary syndrome; current knowledge and future directions: a systematic review. Hormone and Metabolic Research. 2019 May;51(05):279-87. [Google Scholar] [Crossref]

26. Dubey P, Reddy S, Boyd S, Bracamontes C, Sanchez S, Chattopadhyay M, Dwivedi A. Effect of nutritional supplementation on oxidative stress and hormonal and lipid profiles in PCOS-affected females. Nutrients. 2021 Aug 25;13(9):2938. [Google Scholar] [Crossref]

27. Hu X, Wang W, Su X, Peng H, Tan Z, Li Y, Huang Y. Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: a systematic review and network meta-analysis. PeerJ. 2023 Nov 13;11:e16410. [Google Scholar] [Crossref]

28. 28.Dubey P, Thakur V, Chattopadhyay M. Role of minerals and trace elements in diabetes and insulin resistance. Nutrients. 2020 Jun 23;12(6):1864. [Google Scholar] [Crossref]

29. Anderson RA, Polansky MM, Bryden NA, Roginski EE, Mertz W, Glinsmann W. Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables. Metabolism. 1983 Sep 1;32(9):894-9. [Google Scholar] [Crossref]

30. Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. Journal of the American College of Nutrition. 1997 Oct 1;16(5):404-10. [Google Scholar] [Crossref]

31. Capone K, Sentongo T. The ABCs of nutrient deficiencies and toxicities. Pediatric annals. 2019 Nov 1;48(11):e434-40. [Google Scholar] [Crossref]

32. Balali-Mood M, Naseri K, Tahergorabi Z, Khazdair MR, Sadeghi M. Toxic mechanisms of five heavy metals: mercury, lead, chromium, cadmium, and arsenic. Frontiers in pharmacology. 2021 Apr 13;12:643972. [Google Scholar] [Crossref]

33. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum in: Hum Reprod. 2019 Feb 1;34(2):388. doi: 10.1093/humrep/dey363. PMID: 30052961; PMCID: PMC6112576. [Google Scholar] [Crossref]

34. Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C, Pugliese G, Colao A, Savastano S. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients. 2019 Sep 23;11(10):2278. doi: 10.3390/nu11102278. PMID: 31547562; PMCID: PMC6836220. [Google Scholar] [Crossref]

35. Roelfsema F, Liu PY, Takahashi PY, Yang RJ, Veldhuis JD. Dynamic interactions between LH and testosterone in healthy community-dwelling men: impact of age and body composition. The Journal of Clinical Endocrinology & Metabolism. 2020 Mar;105(3):e628-41. [Google Scholar] [Crossref]

36. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, Frearson M, Thondan M, Stepto N, Teede HJ. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. Journal of the Academy of Nutrition and Dietetics. 2013 Apr 1;113(4):520-45. [Google Scholar] [Crossref]

37. Izadi A, Ebrahimi S, Shirazi S, et al. Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism. 2019 Feb;104(2):319-327. DOI: 10.1210/jc.2018-01221. PMID: 30202998. [Google Scholar] [Crossref]

38. Jamilian, Mehri & Bahmani, Fereshteh & Vahedpoor, Zahra & Salmani, Ali & Ebrahimi, Maryam & Jafari, Parvaneh & Dizaji, Shahrzad & Asemi, Zatollah. (2016). Effects of Probiotic Supplementation on Metabolic Status in Pregnant Women: a Randomized, Double-blind, Placebo-Controlled Trial. Archives of Iranian medicine. 19. 687-692. [Google Scholar] [Crossref]

39. Samimi M, Zarezade Mehrizi M, Foroozanfard F, Akbari H, Jamilian M, Ahmadi S, Asemi Z. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017 Apr;86(4):560-566. doi: 10.1111/cen.13288. Epub 2017 Jan 10. PMID: 27911471. [Google Scholar] [Crossref]

40. Genazzani AD, Shefer K, Della Casa D, Prati A, Napolitano A, Manzo A, Despini G, Simoncini T. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest. 2018 May;41(5):583-590. doi: 10.1007/s40618-017-0782-z. Epub 2017 Oct 31. PMID: 29090431. [Google Scholar] [Crossref]

41. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. 2015;2015:817849. doi: 10.1155/2015/817849. Epub 2015 Jan 8. PMID: 25653680; PMCID: PMC4306416. [Google Scholar] [Crossref]

42. Szczuko M, Kikut J, Szczuko U, Szydłowska I, Nawrocka-Rutkowska J, Ziętek M, Verbanac D, Saso L. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review. Nutrients. 2021 Jul 18;13(7):2452. doi: 10.3390/nu13072452. PMID: 34371961; PMCID: PMC8308732. [Google Scholar] [Crossref]

43. Yadav, Sandeep & Rani, Ritu & Khan, Asif & Singh, Anuj & Gautam, Sujain. (2026). Herbal Strategies for Managing Polycystic Ovary Syndrome: A Comprehensive Review of Potential Therapeutics. [Google Scholar] [Crossref]

44. Lakshmi JN, Babu AN, Kiran SSM, Nori LP, Hassan N, Ashames A, Bhandare RR, Shaik AB. Herbs as a Source for the Treatment of Polycystic Ovarian Syndrome: A Systematic Review. BioTech (Basel). 2023 Jan 3;12(1):4. doi: 10.3390/biotech12010004. PMID: 36648830; PMCID: PMC9844343. [Google Scholar] [Crossref]

45. Kort DH, Lobo RA. Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol. 2014 Nov;211(5):487.e1-6. doi: 10.1016/j.ajog.2014.05.009. Epub 2014 May 9. PMID: 24813595. [Google Scholar] [Crossref]

46. Saiyed A, Jahan N, Makbul SAA, Ansari M, Bano H, Habib SH. Effect of combination of Withania somnifera Dunal and Tribulus terrestris Linn on letrozole induced polycystic ovarian syndrome in rats. Integr Med Res. 2016 Dec;5(4):293-300. doi: 10.1016/j.imr.2016.10.002. Epub 2016 Oct 19. PMID: 28462131; PMCID: PMC5390450. [Google Scholar] [Crossref]

47. Bamola, Neelam & Verma, Poonam & Negi, Chandranandani. (2018). A Review on Some Traditional Medicinal Plants. International Journal of Life-Sciences Scientific Research. 4. 10.21276/ijlssr.2018.4.1.7. [Google Scholar] [Crossref]

48. Zhang Y, Guo X, Ma S, Ma H, Li H, Wang Y, Qin Z, Wu X, Han Y, Han Y. The treatment with complementary and alternative traditional Chinese medicine for menstrual disorders with polycystic ovary syndrome. Evidence‐Based Complementary and Alternative Medicine. 2021;2021(1):6678398. [Google Scholar] [Crossref]

49. Takeuchi T, Nishii O, Okamura T, Yaginuma T. Effect of traditional herbal medicine, shakuyaku-kanzo-to on total and free serum testosterone levels. The American journal of Chinese medicine. 1989;17(01n02):35-44. [Google Scholar] [Crossref]

50. Yaginuma T, Izumi R, Yasui H, Arai T, Kawabata M. Effect of traditional herbal medicine on serum testosterone levels and its induction of regular ovulation in hyperandrogenic and oligomenorrheic women (author's transl). Nihon Sanka Fujinka Gakkai Zasshi. 1982 Jul 1;34(7):939-44. [Google Scholar] [Crossref]

51. SHAIKH M. LEAD IDENTIFICATION FOR TREATMENT OF PCOS-A COMPREHENSIVE REVIEW ON CHROMONE ANALOGUES. [Google Scholar] [Crossref]

52. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008 Aug;86(8):594-9. doi: 10.2471/blt.07.042820. PMID: 18797616; PMCID: PMC2649468. [Google Scholar] [Crossref]

53. Chen JT, Tominaga K, Sato Y, Anzai H, Matsuoka R. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Complement Med. 2010 Dec;16(12):1295-9. doi: 10.1089/acm.2009.0696. Epub 2010 Oct 29. PMID: 21034160. [Google Scholar] [Crossref]

54. Yadav, Sandeep & Rani, Ritu & Khan, Asif & Singh, Anuj & Gautam, Sujain. (2026). Herbal Strategies for Managing Polycystic Ovary Syndrome: A Comprehensive Review of Potential Therapeutics. [Google Scholar] [Crossref]

55. 55.Rashid R, Mir SA, Kareem O, Ali T, Ara R, Malik A, Amin F, Bader GN. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese Journal of Obstetrics and Gynecology. 2022 Jan 1;61(1):40-50. [Google Scholar] [Crossref]

56. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2017(11). [Google Scholar] [Crossref]

57. Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic advances in endocrinology and metabolism. 2020 Jul;11:2042018820938305. [Google Scholar] [Crossref]

58. Palavicini JP, Chavez-Velazquez A, Fourcaudot M, Tripathy D, Pan M, Norton L, DeFronzo RA, Shannon CE. The insulin-sensitizer pioglitazone remodels adipose tissue phospholipids in humans. Frontiers in Physiology. 2021 Dec 2;12:784391. [Google Scholar] [Crossref]

59. Manna MJ, Jabur MS, Alsabah AS, Baqir LS. A Review on new drugs for treatment of Polycystic Ovarian Syndrome. Karbala Journal of Pharmaceutical Sciences. 2023 Jan 1;1(21). [Google Scholar] [Crossref]

60. Kutaif RH, Alabbassi MG, Hussein WA, Hassan ZF, Ali SK. Comparative effectiveness of pioglitazone, raloxifene, and combined pioglitazone-raloxifene of ovulation-induction therapies in infertile patients with resistant polycystic ovary syndrome. Sys Rev Pharm. 2020 Dec 1;11(12):1876-81. [Google Scholar] [Crossref]

61. Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones. 2018 Sep;17(3):333-50. [Google Scholar] [Crossref]

62. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, Nowak A, Madej P. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. International journal of molecular sciences. 2022 Apr 14;23(8):4334. [Google Scholar] [Crossref]

63. Papaetis GS, Filippou PK, Constantinidou KG, Stylianou CS. Liraglutide: new perspectives for the treatment of polycystic ovary syndrome. Clinical drug investigation. 2020 Aug;40(8):695-713. [Google Scholar] [Crossref]

64. Barnett A. DPP‐4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice. 2006 Nov;60(11):1454-70. [Google Scholar] [Crossref]

65. Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocrine Practice. 2018 Jan 1;24(1):69-77. [Google Scholar] [Crossref]

66. Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocrine Practice. 2018 Jan 1;24(1):69-77. [Google Scholar] [Crossref]

67. Marinkovic-Radosevic J, Berkovic MC, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World journal of diabetes. 2021 Jul 15;12(7):932. [Google Scholar] [Crossref]

68. Sirotkin AV, Schaeffer HJ. Direct regulation of mammalian reproductive organs by serotonin and melatonin. Journal of Endocrinology. 1997 Jul 1;154(1):1-5. [Google Scholar] [Crossref]

69. Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition. 2019 Feb 1;38(1):191-6. [Google Scholar] [Crossref]

70. Shabani A, Foroozanfard F, Kavossian E, Aghadavod E, Ostadmohammadi V, Reiter RJ, Eftekhar T, Asemi Z. Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Journal of affective disorders. 2019 May 1;250:51-6. [Google Scholar] [Crossref]

71. Teede HJ, Joham AE, Paul E, et al. Optimising management of polycystic ovary syndrome across the lifespan. Nat Rev Endocrinol. 2022;18(4):235–248. doi:10.1038/s41574-021-00602-8. [Google Scholar] [Crossref]

72. Torabi S, Benetti A, Parizad N, et al. Digital health interventions for lifestyle management in women with polycystic ovary syndrome. BMC Womens Health. 2021;21(1):1–11. doi:10.1186/s12905-021-01495-0. [Google Scholar] [Crossref]

73. Piltonen TT, Chen ZJ, Eriksson H, et al. Omics approaches in polycystic ovary syndrome: from pathogenesis to precision medicine. Trends Endocrinol Metab. 2023;34(3):180–194. doi:10.1016/j.tem.2022.12.004. [Google Scholar] [Crossref]

74. Palomba S, Santagni S, Falbo A, La Sala GB. Assisted reproductive technologies in women with polycystic ovary syndrome: advances and challenges. Hum Reprod Update. 2020;26(5):751–769. doi:10.1093/humupd/dmaa023. [Google Scholar] [Crossref]

75. Dokras A, Saini S, Gibson-Helm M, et al. Telehealth and virtual care for women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(7):e2747–e2756. doi:10.1210/clinem/dgab187. [Google Scholar] [Crossref]

76. Wang R, Li W, Bordewijk EM, et al. Application of artificial intelligence in diagnosis and management of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022;13:910524. doi:10.3389/fendo.2022.910524. [Google Scholar] [Crossref]

77. Lujan ME, Jarrett BY, Brooks ED, et al. Improved ultrasonographic techniques for assessment of ovarian morphology in PCOS. Ultrasound Obstet Gynecol. 2020;56(5):754–761. doi:10.1002/uog.21956. [Google Scholar] [Crossref]

78. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbiome and polycystic ovary syndrome: new insights and future perspectives. Nat Rev Endocrinol. 2021;17(4):229–240. doi:10.1038/s41574-020-00438-7. [Google Scholar] [Crossref]

79. Rastogi S, Modi A, Sathian B. Ayurvedic research a bibliometric analysis of research publications output during 2002–2011. Journal of Ayurveda and Integrative Medicine. 2017; 8: 190-197. [Google Scholar] [Crossref]

80. Meher K. An Ayurvedic approach of pcod a review article. World Journal of Pharmaceutical Research. 2023. [Google Scholar] [Crossref]

81. Huang Z, Chavda VP, Bezbaruah R, et al. An Ayurgenomics Approach Prakriti-Based Drug Discovery and Development for Personalized Care. Front Pharmacol. 2022; 13: 866827. [Google Scholar] [Crossref]

82. Bashir A, Guha L, Bhat IA. Comprehension, management, and treatment of polycystic ovarian syndrome via allopathic, unani and ayurvedic perspectives. Journal of Gynecology and Womens Health. 2021; 21. [Google Scholar] [Crossref]

83. Kumari S, Singh SK, Rajoria K, et al. An Ayurvedic Approach in Management of Poly Cystic Ovarian Syndrome. International Journal of Ayurvedic Medicine. 2020; 11: 644- 649. [Google Scholar] [Crossref]

84. Patil SM, Patil VA. A review of management of Polycystic Ovarian Syndrome through Ayurveda. JAIMS. 2021; 6: 161- 165. [Google Scholar] [Crossref]

85. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. doi: 10.1038/nrdp.2016.57. PMID: 27510637. [Google Scholar] [Crossref]

86. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004. Epub 2018 Jul 19. PMID: 30033227; PMCID: PMC6939856. [Google Scholar] [Crossref]

87. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. doi: 10.1210/edrv.18.6.0318. PMID: 9408743. [Google Scholar] [Crossref]

88. Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Adv Nutr. 2022 Aug 1;13(4):1243-1266. doi: 10.1093/advances/nmab141. PMID: 34970669; PMCID: PMC9340985. [Google Scholar] [Crossref]

89. Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011 May;164(5):741-9. doi: 10.1530/EJE-11-0134. Epub 2011 Mar 9. PMID: 21389086. [Google Scholar] [Crossref]

90. Mohan A, Haider R, Fakhor H, Hina F, Kumar V, Jawed A, Majumder K, Ayaz A, Lal PM, Tejwaney U, Ram N, Kazeem S. Vitamin D and polycystic ovary syndrome (PCOS): a review. Ann Med Surg (Lond). 2023 Jun 5;85(7):3506-3511. doi: 10.1097/MS9.0000000000000879. PMID: 37427232; PMCID: PMC10328709. [Google Scholar] [Crossref]

91. Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C, Pugliese G, Colao A, Savastano S. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients. 2019 Sep 23;11(10):2278. doi: 10.3390/nu11102278. PMID: 31547562; PMCID: PMC6836220. [Google Scholar] [Crossref]

92. Marsh KA, Steinbeck KS, Atkinson FS, Petocz P, Brand-Miller JC. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr. 2010 Jul;92(1):83-92. doi: 10.3945/ajcn.2010.29261. Epub 2010 May 19. PMID: 20484445. [Google Scholar] [Crossref]

93. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, Frearson M, Thondan M, Stepto N, Teede HJ. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013 Apr;113(4):520-45. doi: 10.1016/j.jand.2012.11.018. Epub 2013 Feb 16. PMID: 23420000. [Google Scholar] [Crossref]

94. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013 May-Jun;19(3):268-88. doi: 10.1093/humupd/dms059. Epub 2013 Jan 9. PMID: 23303572. [Google Scholar] [Crossref]

95. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. 2015;2015:817849. doi: 10.1155/2015/817849. Epub 2015 Jan 8. PMID: 25653680; PMCID: PMC4306416. [Google Scholar] [Crossref]

96. Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M. Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. Nutrients. 2021 Oct 1;13(10):3491. doi: 10.3390/nu13103491. PMID: 34684492; PMCID: PMC8539968. [Google Scholar] [Crossref]

97. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May;14(5):270-284. doi: 10.1038/nrendo.2018.24. Epub 2018 Mar 23. PMID: 29569621. [Google Scholar] [Crossref]

• Assessment of the Role of Artificial Intelligence in Repositioning TVET for Economic Development in Nigeria
• Teachers’ Use of Assure Model Instructional Design on Learners’ Problem Solving Efficacy in Secondary Schools in Bungoma County, Kenya
• “E-Booksan Ang Kaalaman”: Development, Validation, and Utilization of Electronic Book in Academic Performance of Grade 9 Students in Social Studies
• Analyzing EFL University Students’ Academic Speaking Skills Through Self-Recorded Video Presentation
• Major Findings of The Study on Total Quality Management in Teachers’ Education Institutions (TEIs) In Assam – An Evaluative Study